The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.

Gilead Sciences is expanding beyond its core HIV business with four potential drug launches in 2026, including treatments for hepatitis delta virus, multiple myeloma, and breast cancer. Despite strong financials (Q1 revenue up 4% YoY, EPS up 54.8%), the stock has only risen 9% this year. The company's strategic acquisitions and diversified pipeline, combined with no major patent cliffs until 2036 and an attractive 2.39% dividend yield, suggest investors are undervaluing the company's growth potential.

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

BBG Advanced Therapies, a subsidiary of BioBridge Global, has partnered with Kite (a Gilead Company) to deploy a Mobile Leukapheresis Center across Texas. This first-of-its-kind platform brings T-cell collection directly to patients' communities, reducing travel burdens and expanding access to Kite's CAR T-cell therapies for blood cancer treatment. The initiative addresses the gap where only 2 in 10 eligible U.S. patients currently receive these treatments.

Gilead Sciences and Merck discontinued their Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda for lung cancer after the combination failed to reach statistical significance in progression-free survival with low probability of overall survival benefit. However, the companies reported positive Phase 3 results for an investigational once-weekly oral HIV regimen combining islatravir and lenacapavir, which met its primary efficacy endpoints in two studies.

Gilead Sciences announced positive Phase 3 IDEAL study results for Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC). The drug significantly improved alkaline phosphatase (ALP) normalization compared to placebo in patients with inadequately controlled disease. The company plans to present full data at a medical congress and engage with regulatory authorities. However, GILD shares fell 2.01% on the news.

RTW Investments, a biotech-focused fund, purchased 11.8 million shares of Tango Therapeutics for approximately $164.37 million in Q1 2026, increasing its stake to roughly 3% of AUM. The purchase comes as TNGX stock has surged 840% over the past year. The investment reflects confidence in Tango's lead candidate vopimetostat and upcoming clinical data for MTAP-deleted cancers, with the company well-funded through 2028.

Oorja Bio, a new clinical-stage biopharmaceutical company, announced a $30 million Series A funding round from Westlake BioPartners to develop ORJ-001, a first-in-class peptide therapeutic for idiopathic pulmonary fibrosis (IPF). The company has received FDA IND clearance and plans to initiate Phase 2 clinical trials in 2026. ORJ-001 is designed to restore alveolar epithelial type 2 (AEC2) cell function to promote lung repair and reverse fibrosis, addressing a significant unmet medical need in IPF treatment.

Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.

Assembly Biosciences announced that its Chief Medical Officer, Anuj Gaggar, MD, PhD, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The company also highlighted positive Phase 1b data for its helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes treatment, with additional data selected for oral presentation and late-breaker poster presentation at ESCMID Global 2026.

Assembly Biosciences reported Q1 2026 financial results with cash reserves of $226.6 million, sufficient to fund operations into 2028. The company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 (licensed to Gilead) and chronic toxicology studies for hepatitis delta virus candidate ABI-6250, with Phase 2 initiation expected in Q4 2026. Net loss was $9.1 million for the quarter.